The strong selling season with record new covered lives and near-100% retention sets up a robust 2027 pipeline. Monitor Q4 revenue trajectory against the raised full-year guidance and the pace of share repurchase execution under the remaining $51M authorization.
Price Chart
Executive Summary
Progyny reported Q3 2026 revenue of $341.3M (+8.9% YoY) and GAAP EPS of $0.32, with adjusted EPS of $0.52. The company raised the midpoint of its full-year 2026 guidance, citing record selling season results of 1.3M new covered lives and near-100% retention. Gross margin expanded 130 bps to 24.5%, while adjusted EBITDA grew 6.3% to $58.4M.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $341.3M, up 8.9% YoY from $313.3M
- GAAP diluted EPS $0.32 vs $0.15 YoY; adjusted EPS $0.52 vs $0.45 YoY
- Gross margin 24.5%, up 130 bps from 23.2% YoY
- Adjusted EBITDA $58.4M, up 6.3% YoY
- Record selling season: 1.3M new covered lives, over 85 new clients, near-100% retention
- Full-year 2026 revenue guidance raised to $1.365B-$1.385B (midpoint up from prior $1.385B midpoint)
- 607 clients as of Sep 30, 2026, up from 553 a year ago
- Repurchased nearly 3M shares for $82.7M in Q3; $51M remaining under buyback authorization
Financial Impact
Revenue growth of 8.9% YoY, gross profit up 15%, net income up 89% YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Fertility benefit services | $223.4M | +10.6% |
| Pharmacy benefit services | $117.9M | +5.8% |
Risk Factors
- Member engagement variability could affect utilization rates and revenue
- Dependence on employer-sponsored benefit plans makes the company sensitive to macroeconomic conditions and employer benefits spending
- Large client concentration risk; a prior large client did not renew for 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551306-26-000163 |
| Document: pgny-20261104.htm | 0001551306-26-000163 |
| Document: progyny3q2026earningssup.htm | 0001551306-26-000163 |
| Document: 0001551306-26-000163-index-headers.html | 0001551306-26-000163 |
| Document: 0001551306-26-000163-index.html | 0001551306-26-000163 |
| Document: 0001551306-26-000163.txt | 0001551306-26-000163 |
| 8-K Data (Synthetic) | 0001551306-26-000163 |
Track record
26 reports on PGNY
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +6.43% at T+5 after the Nov 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $36.75 Now $37.15 +1.09% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Bearish 4/10 Entry $36.18 Now $37.15 −2.68% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $36.58 Now $37.15 +1.56% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $36.50 Now $37.15 +1.78% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $36.43 Now $37.15 +1.98% settles Nov 17
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $34.84 to $36.18 Now $37.15 +6.63% ▲ +3.85% +1.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $34.84 to $36.18 Now $37.15 +6.63% ▲ +3.85% +1.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $34.84 to $36.18 Now $37.15 +6.63% ▲ +3.85% +1.25% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $34.37 to $36.58 Now $37.15 +8.09% ▲ +6.43% +3.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers